Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
The hearing was held less than two months after Sanofi, Novo Nordisk and Eli Lilly announced that they would cap the cost of insulin and drugs used by patients with diabetes.
This Week in Washington: Debt Limit fight continues; Disagreements arise during Senate HELP Committee mark-up of PBM and Generic Drug Competition Bills.
Eli Lilly, Novo Nordisk and Sanofi control 90% of the insulin market in the U.S, where a quarter of all health-care spending is on people with diabetes.